BRCA1 and breast cancer: Initially classified as an HR deficient cancer treatment, olaparib has been approved by FDA for the treatment of serous ovarian cancer as well as breast cancer having a mutation in BRCA1 or BRCA2 germline (Min and Im, 2020).